Abstract
During the ongoing COVID-19 pandemic, there have been burgeoning efforts to develop and deploy smartphone apps to expedite contact tracing and risk notification. Unfortunately, the success of these apps has been limited, partly owing to poor interoperability with manual contact tracing, low adoption rates, and a societally sensitive trade-off between utility and privacy. In this work, we introduce a new privacy-preserving and inclusive system for epidemic risk assessment and notification that aims to address the above limitations. Rather than capturing pairwise encounters between smartphones as done by existing apps, our system captures encounters between inexpensive, zero-maintenance, small devices carried by users, and beacons placed in strategic locations where infection clusters are most likely to originate. Epidemiological simulations using an agent-based model demonstrate several beneficial properties of our system. By achieving bidirectional interoperability with manual contact tracing, our system can help control disease spread already at low adoption. By utilizing the location and environmental information provided by the beacons, our system can provide significantly higher sensitivity and specificity than existing app-based systems. In addition, our simulations also suggest that it is sufficient to deploy beacons in a small fraction of strategic locations for our system to achieve high utility.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
No external funding was received.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All the data used in the study is publicly available and is anonymized.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Code and data to reproduce our epidemiological simulations are available at https://github.com/covid19-model/simulator/tree/beacon.
